Renal Artery Brachytherapy for Sympathetic Renal Denervation for the Treatment of Resistant Hypertension: Preclinical safety study Ron Waksman, Issi Barbash,

Slides:



Advertisements
Similar presentations
FACET - European Journal of Cancer Care March 2006 slides available at: Stereotactic radiosurgery Gordon, K. 1.
Advertisements

Hypertrophy Arrhythmia Oxygen Consumption Vasoconstriction Atherosclerosis Insulin Resistance Renal Sympathetic Afferent Nerves: Kidney as Origin of Central.
RDN for hypertension: Physiological rationale Dr.C.Venkata S.Ram.
RENAL SYMPATHETIC DENERVATION Anxiolytic for nervous kidneys???
Stents Are Not Enough: Statins Keith Channon Department of Cardiovascular Medicine University of Oxford John Radcliffe Hospital, Oxford.
Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by.
EnligHTN™ I, First-in-Human Multicenter Study of a Multi-Electrode Renal Denervation Catheter in Patients with Drug-Resistant Hypertension Vasilios Papademetriou,
Hypertension and The Kidney Update: Clinical Trials Paul J. Scheel, Jr., M.D. Director, Division of Nephrology The Johns Hopkins University School of Medicine.
Stereotactic Radiosurgery Jimmy Johannes Physics 335 – Spring 2004 Final Presentation
Radiofrequency Ablation of Lung Cancer
Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.
Radiotherapy to the female pelvis
1 Overview of Gamma Knife ® Surgery Dr. Sandra Vermeulen, M.D. Swedish Cancer Institute Northwest Hospital Gamma Knife Center Seattle, Washington Learn.
Learn More At: Dose-Response and Dose- Complications Relationships in Stereotactic Radiosurgery for Trigeminal Neuralgia Sandra.
Trials of radiation to prevent or reduce in-stent restenosis Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director.
Alternative Approach Trans-Ulnar Approach Feasibility of Percutaneous Coronary Intervention Via Transulnar Artery Approach in Selected Patients with Coronary.
Radiation for restenosis: the dark side of arteries Robert S Schwartz MD Professor of Medicine Mayo Clinic Rochester, MN.
A Controlled Trial of Renal Denervation for Resistant Hypertension
Renal denervation for resistant hypertension: it’s time to reconsider!
THE IMPLEMENTATION OF ABLATIVE HYPOFRACTIONATED RADIOTHERAPY FOR STEREOTACTIC TREATMENTS IN THE BRAIN AND BODY: OBSERVATIONS ON EFFICACY AND TOXICITY IN.
Renal Sympathetic Denervation View From the EU
Vasilios Papademetriou, MD
Prairie Cardiovascular, Springfield, IL US
Eberhard Grube MD, FACC, FSCAI
Critical Appraisal of Devices for the Management of Hypertension
Pros and Cons of Radial Access
DANTE PAZZANESE INSTITUTE OF CARDIOLOGY, SÃO PAULO, BRAZIL
Rationale for Radiation Therapy for Nerve Denervation
Renal Nerve Ablation: Will It Become the treatment
Thomas F. Lüscher, FESC, FAHA, FRCP
Catheter-based Renal Denervation with the Symplicity System Provides Safe and Durable Blood Pressure Reduction out to Three Years Horst Sievert1, Henry.
Obstructive Hypertrophic Cardiomyopathy
Potential conflicts of interest
OneShot™ Renal Denervation System
Hypofractionated radiotherapy for breast cancer
Critical Appraisal of the Current Ongoing Study Designs
Innovation Session CRT Meeting Washington, D.C. February 22, 2014
John C. Somberg, MD I have no real or apparent conflicts of interest to report.
From ESH 2016 | POS 7D: Jan Rosa, MD
Vascular Brachytherapy Renal Denervation for Resistant Hypertension
Sympathetic Nerve Denervation for Treatment of Hypertension
Accelerating a Revolution in the Treatment of Hypertension
Medtronic Cardiovascular,
A randomized controlled trial of distal renal denervation vs conventional mode of the intervention for treatment of resistant hypertension Stanislav Pekarskiy.
Edward Howard MBChB(Hons) PhD Robert Lager MD Augusto Pichard MD
Mapping Sympathetic Nerve Distribution for
Chemical Renal Denervation Update and Future Directions
Local Drug Delivery for Renal Denervation
Drug Eluting Balloons Bodo Cremers, MD
When IVUS? When FFR? Assessing Intermediate Lesions
The Ardian Catheter Based Approach to Renal Denervation to Treat Refractory HTN: Results of the EU Randomized Clinical Trial Krishna Rocha-Singh, M.D.,
Renal Sympathetic Denervation: The Academic View
TECHNOLOGY UPDATE TIVUS (Cardiosonic)
Pre-Clinical Evaluation of Renal Denervation with RF Technologies Meital Mazor, PhD Vessix Vascular, Boston Scientific.
Kirk P. Seward, PhD President and Chief Technology Officer
Renal Denervation Two Late-Breaking Clinical Trials.
Diastolic heart failure
Thank you for taking the preassessment
Resistant Hypertension: Initial Combinations of Medications
Renal Denervation Industry Perspective
Controlling High Blood Pressure
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
The American College of Cardiology Presented by Dr. Raimund Erbel
The following slides highlight a report on a presentation at a Late-Breaking Trial Session of the European Society of Cardiology Congress 2004 held in.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Correlation between endothelial function and hypertension
Volume 377, Issue 9771, Pages (March 2011)
Updated 3-Year Meta-Analysis of the TAXUS Clinical Trials Safety and Efficacy Demonstrated in 3,445 Randomized Patients Time allocation for this talk.
Clinician Referral Training
DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.
Presentation transcript:

Renal Artery Brachytherapy for Sympathetic Renal Denervation for the Treatment of Resistant Hypertension: Preclinical safety study Ron Waksman, Issi Barbash, Renu Virmani MedStar Washington Hospital Center

I/we have no real or apparent conflicts of interest to report. Israel M. Barbash, MD I/we have no real or apparent conflicts of interest to report.

Background Renal sympathetic efferent and afferent nerves lie immediately adjacent to the wall of the renal arteries Historical experience of radical surgical approaches for sympathetic denervation were successful in lowering BP with the cost of high rates of morbidity and mortality Renal sympathetic denervation was achieved more recently with a percutaneous catheter based approach utilizing radio frequency ablation And play significant role in pathophysiology of HTN

SYMPLICITY HTN-2: Office BP was reduced in resistant HTN patients In patients with RHTN, Data from Showed At 6 mo f/u SYMPLICITY HTN-2, Lancet 2010

SYMPLICITY HTN-1, 2 year follow-up: In patients with resistant hypertension, catheter-based renal sympathetic denervation results in a substantial reduction in BP sustained out to 2 years 2 yr f/u from Showed paersistent decrease Up to 24 mo And data from other RF systems continue to accumulate showing comparable efficacy SYMPLICITY HTN-1, Hypertension 2011

Limitations of RF-ablation mediated-renal denervation Potential damage to vascular endothelium with late vascular stenosis Pain associated with the ablation Need for multiple ablations resulting in long procedure time RF energy

A novel approach for renal denervation by β-radiation using Beta-Cath™ 3.5F System (Novoste) Potential “sparing” of endothelial injury Limited perivascular effect Small sheath size Short procedure time Our purpose was to test a .. No pain

Clinical and histologic (arrows) neuropathies were Radiation-mediated nerve damage was initially identified after intraoperative radiotherapy. Clinical and histologic (arrows) neuropathies were documented after a dose of only 35 Gy Theoretical support for this approach comes from studies like this, showing that LeCouteur et al. Int J Rad Oncol Biol Phys 1989

Gamma knife radiosurgery is used routinely for nerve ablation in trigeminal neuralgia Radiation dosages of 80-90 Gy in a 4-mm isocenter. Long term effects of up to 3 years f/u. Animal histology indicates that gamma knife radiosurgery creates localized, irreversible nerve damage. Similarly, Delayed enhancement by MRI indicates fibrosis of the trigeminal nerves Park et al. J Clinical Neuro 2011, Kondziolka et al. Neurosurg 2000

β-radiation induces linear myocardial lesions The isthmus was irradiated by Beta-Cath catheter ([Sr/Y]-90, Novoste) in 8 dogs. High dose radiation created effective bidirectional block: High dose radiation was safe: Did not damage the endothelium Created localized transmural lesion 25 Gy 50 Gy n 2 6 Conduction block Immediate None Late (>1 week) 1/2 6/6 With regards to safety lesion Guerra & Bonan, Circulation 2004

β-radiation has been used to treat ISR in the renal arteries Patient Age Dose (Gy) F/U (mo) Adverse events 1 65 20.7 7 None 2 5 3 71 16.9 4 70 22.15 62 21.00 We have a lot of experience with brachytherapy in the coronaries Jahraus et al. Southern Med J 2003

Methods 10 naïve Yorkshire swine β -emitting radiation dose of 25 or 50 Gy was delivered to the main renal artery Follow-up of 1-2 months: Angiography IVUS Histology* * Data available for 1 month follow up

Renal artery angiography showed no angiographic stenosis up to 2 months follow-up Baseline angio BetaCath location 2 mo f/u

IVUS showed no endothelial or adventitial damage Baseline 1 month 2 months

Nerve injury assessment Perivascular nerve fascicles with mild cellular degeneration, inflammation and fibrosis Hypocellular fascicles with cellular degeneration and perineural inflammation In terms of efficacy, these are 2 H&E slides 2nd: High power mag showing

Nerve injury assessment This slide summarize the histolgy quantification of the Dose response effect

Vascular injury assessment Focal adventitial fibrosis with myxoid change Arteriolar fibrinoid necrosis periarteriolar chronic inflammation In terms of And damage only to With sparing of the endothelium of the main vessel

Vascular injury assessment This slide summarize the histolgy quantification of the

Conclusions Renal denervation using β-emitting radiation is feasible In the tested dosages (25-50 Gy) there is minimal vascular damage β-emitting radiation can cause renal nerve damage Further clinical studies are required to assess efficacy If proven effective, dedicated device should be developed Our preliminary results indicate